LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Lori, Franco"
  2. AU="Sevalie, Stephen S"
  3. AU="Haeussler, Maximillian"
  4. AU=Segura de la Cal Teresa
  5. AU=Kupferschmidt Kai
  6. AU="Di Silvio, Lucy"
  7. AU="Taixian Li"
  8. AU="Diederich, Jonathan"
  9. AU="Sandra M. Frei"
  10. AU="Vasaikar, Suhas"
  11. AU="Arango, Jesus"
  12. AU="Scott, C. Tim"
  13. AU="Coelho, Luis Francisco Mello(Universidade Estadual Paulista Instituto de Biociências Departamento de Botânica)"
  14. AU="Hesong Zeng"
  15. AU="Babey, Anna-Marie"
  16. AU="Stich, H"
  17. AU=Kuitunen I
  18. AU="Biscaye Pierre E"
  19. AU="Saha, Somen"
  20. AU="Liu, Weihuang"
  21. AU="Nijhuis, Monique"
  22. AU="Ye, Jin-Rong"
  23. AU="Van Not, Hans Pieter"
  24. AU="Liang, Xiao-Hui"
  25. AU="Romano, Raffaella"
  26. AU="Gilles Subra"
  27. AU="Potocnik, Ana"
  28. AU="Butt, Christine"

Suchergebnis

Treffer 1 - 10 von insgesamt 59

Suchoptionen

  1. Buch ; Konferenzbeitrag: Immunomodulating drugs for the treatment of HIV/AIDS

    Lori, Franco

    conference report from the Research Institute for Genetic and Human Therapy (Instituto di Ricerca per la Terapia Genetica Umana; RIGHT) ; September 9 - 10, 2004, Poiano (Lake Garda), Italy

    (Journal of acquired immune deficiency syndromes ; 42, Suppl. 1)

    2006  

    Körperschaft Research Institute for Genetic and Human Therapy
    Verfasserangabe guest co-eds. Franco Lori
    Serientitel Journal of acquired immune deficiency syndromes ; 42, Suppl. 1
    Überordnung
    Sprache Englisch
    Umfang S27 S. : graph. Darst.
    Verlag Lippincott Williams & Wilkins
    Erscheinungsort Hagerstown, MD
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch ; Konferenzbeitrag
    HBZ-ID HT014806796
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    SignaturLeihstatusStandort
    Zs A 2442 -42,Suppl.1- nicht ausleihbar Zeitschriften-Lesesaal

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Konferenzbeitrag: Immune reconstitution and control of HIV

    Lori, Franco

    June 5 - 6, 2003, Stresa, Italy ; conference report

    2004  

    Verfasserangabe Franco Lori
    Sprache Englisch
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Artikel ; Konferenzbeitrag
    Anmerkung In: HIV clinical trials. - ISSN 1528-4336. - 5 (2004),3, S. 170 - 182
    HBZ-ID HT014111414
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    SignaturLeihstatusStandort
    Zs A 5543 -5- nicht ausleihbar Zeitschriften-Lesesaal

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Buch ; Konferenzbeitrag: Targeting HIV reservoires and reconstituting the immune system

    Lori, Franco

    April 18 - 19, 1999, Washington, D.C. ; conference summary

    (AIDS research and human retroviruses ; 15,18 ; Annual meeting / Research Institute for Genetic and Human Therapy ; 2)

    1999  

    Veranstaltung/Kongress Meeting on Targeting HIV Reservoirs and Reconstituting the Immune System (2, 1999, WashingtonDC)
    Verfasserangabe [Second Annual Meeting on "Targeting HIV Reservoirs and Reconstituting the Immune System"]. Guest ed.: Franco Lori
    Serientitel AIDS research and human retroviruses ; 15,18
    Annual meeting / Research Institute for Genetic and Human Therapy ; 2
    RIGHT ... annual meeting
    Aids research and human retroviruses
    Überordnung RIGHT ... annual meeting
    Aids research and human retroviruses
    Sprache Englisch
    Umfang S. 1597 - 1741 : Ill., graph. Darst.
    Verlag Liebert
    Erscheinungsort Larchmont, NY
    Erscheinungsland Vereinigtes Königreich
    Dokumenttyp Buch ; Konferenzbeitrag
    HBZ-ID HT011174672
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    SignaturLeihstatusStandort
    Zs A 1928 -15- nicht ausleihbar Zeitschriften-Lesesaal

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.

    Lori, Franco

    Expert review of vaccines

    2011  Band 10, Heft 10, Seite(n) 1371–1384

    Abstract: The HIV global pandemic continues to rage with over 33 million people living with the disease. Although multidrug therapy has improved the prognosis for those infected by the virus, it has not eradicated the infection. Immunological therapies, including ... ...

    Abstract The HIV global pandemic continues to rage with over 33 million people living with the disease. Although multidrug therapy has improved the prognosis for those infected by the virus, it has not eradicated the infection. Immunological therapies, including therapeutic vaccines, are needed to supplement drug therapy in the search for a 'functional cure' for HIV. DermaVir (Genetic Immunity Kft, Budapest, Hungary and McLean, Virginia, USA), an experimental HIV/AIDS therapeutic vaccine, combines three key elements of rational therapeutic vaccine design: a single plasmid DNA (pDNA) immunogen expressing 15 HIV antigens, a synthetic pDNA nanomedicine formulation and a dendritic cell-targeting topical-vaccine administration. DermaVir's novel mechanism of action, natural transport by epidermal Langerhans cells to the lymph nodes to express the pDNA-encoded HIV antigens and induce precursor/memory T cells with high proliferation capacity, has been consistently demonstrated in mouse, rabbit, primate and human subjects. Safety, immunogenicity and preliminary efficacy of DermaVir have been clinically demonstrated in HIV-infected human subjects. The DermaVir technology platform for dendritic cell-based therapeutic vaccination might offer a new treatment paradigm for cancer and infectious diseases.
    Mesh-Begriff(e) AIDS Vaccines/administration & dosage ; AIDS Vaccines/therapeutic use ; Animals ; Humans ; Mice ; Nanomedicine ; Plasmids ; Rabbits ; Vaccines, DNA/therapeutic use
    Chemische Substanzen AIDS Vaccines ; DermaVir ; Vaccines, DNA
    Sprache Englisch
    Erscheinungsdatum 2011-10
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2181284-6
    ISSN 1744-8395 ; 1476-0584
    ISSN (online) 1744-8395
    ISSN 1476-0584
    DOI 10.1586/erv.11.118
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6077: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients.

    De Forni, Davide / Poddesu, Barbara / Cugia, Giulia / Chafouleas, James / Lisziewicz, Julianna / Lori, Franco

    PloS one

    2022  Band 17, Heft 11, Seite(n) e0276751

    Abstract: Despite new antivirals are being approved against SARS-CoV-2 they suffer from significant constraints and are not indicated for hospitalized patients, who are left with few antiviral options. Repurposed drugs have previously shown controversial clinical ... ...

    Abstract Despite new antivirals are being approved against SARS-CoV-2 they suffer from significant constraints and are not indicated for hospitalized patients, who are left with few antiviral options. Repurposed drugs have previously shown controversial clinical results and it remains difficult to understand why certain trials delivered positive results and other trials failed. Our manuscript contributes to explaining the puzzle: this might have been caused by a suboptimal drug exposure and, consequently, an incomplete virus suppression, also because the drugs have mostly been used as add-on monotherapies. As with other viruses (e.g., HIV and HCV) identifying synergistic combinations among such drugs could overcome monotherapy-related limitations. In a cell culture model for SARS-CoV-2 infection the following stringent criteria were adopted to assess drug combinations: 1) identify robust, synergistic antiviral activity with no increase in cytotoxicity, 2) identify the lowest drug concentration inhibiting the virus by 100% (LIC100) and 3) understand whether the LIC100 could be reached in the lung at clinically indicated drug doses. Among several combinations tested, remdesivir with either azithromycin or ivermectin synergistically increased the antiviral activity with no increase in cytotoxicity, improving the therapeutic index and lowering the LIC100 of every one of the drugs to levels that are expected to be achievable and maintained in the lung for a therapeutically relevant period of time. These results are consistent with recent clinical observations showing that intensive care unit admission was significantly delayed by the combination of AZI and RDV, but not by RDV alone, and could have immediate implications for the treatment of hospitalized patients with COVID-19 as the proposed "drug cocktails" should have antiviral activity against present and future SARS-CoV-2 variants without significant overlapping toxicity, while minimizing the onset of drug resistance. Our results also provide a validated methodology to help sort out which combination of drugs are most likely to be efficacious in vivo, based on their in vitro activity, potential synergy and PK profiles.
    Mesh-Begriff(e) Humans ; SARS-CoV-2 ; COVID-19/drug therapy ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Adenosine Monophosphate/pharmacology ; Adenosine Monophosphate/therapeutic use ; Alanine/pharmacology ; Alanine/therapeutic use ; Lung ; Drug Combinations
    Chemische Substanzen Antiviral Agents ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX) ; Drug Combinations
    Sprache Englisch
    Erscheinungsdatum 2022-11-10
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0276751
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Treating HIV/AIDS by reducing immune system activation: the paradox of immune deficiency and immune hyperactivation.

    Lori, Franco

    Current opinion in HIV and AIDS

    2008  Band 3, Heft 2, Seite(n) 99–103

    Abstract: Purpose of review: To collect published evidence in support of a novel immune therapeutic approach to reduce the excess of immune activation that ultimately turns into immune deficiency in HIV/AIDS.: Recent findings: A large body of evidence has been ...

    Abstract Purpose of review: To collect published evidence in support of a novel immune therapeutic approach to reduce the excess of immune activation that ultimately turns into immune deficiency in HIV/AIDS.
    Recent findings: A large body of evidence has been collected in support of the pathogenetic interpretation that prolonged immune overactivation induced by HIV during the course of chronic infection exhausts the immune system and leads to AIDS. Some groups are exploring the possibility of therapeutic interventions to limit the immune system overload. Cytostatic drugs appear promising candidates to achieve the goal, as they restrain cell proliferation without blocking it. At the same time, they do not affect cellular response to antigenic stimulation, and at appropriate dosages are not immune suppressive.
    Summary: Presently available antiretrovirals only partially reduce immune system activation during chronic HIV infection. Further clinical research is warranted to test cytostatic drugs to avert immune overactivation and prevent progression to AIDS.
    Sprache Englisch
    Erscheinungsdatum 2008-03
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2502511-9
    ISSN 1746-6318 ; 1746-630X
    ISSN (online) 1746-6318
    ISSN 1746-630X
    DOI 10.1097/COH.0b013e3282f525cf
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 6812: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Fas, IL-7, and T cells: live and let die.

    Lori, Franco

    Blood

    2008  Band 112, Heft 4, Seite(n) 930–931

    Sprache Englisch
    Erscheinungsdatum 2008-08-06
    Erscheinungsland United States
    Dokumenttyp Comment ; Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2008-05-156695
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh III Zs.140: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  8. Artikel ; Online: SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves.

    Manna, Antonio / De Forni, Davide / Bartocci, Marco / Pasculli, Nicola / Poddesu, Barbara / Lista, Florigio / De Santis, Riccardo / Amatore, Donatella / Grilli, Giorgia / Molinari, Filippo / Sangiovanni Vincentelli, Alberto / Lori, Franco

    Viruses

    2023  Band 15, Heft 7

    Abstract: Coronaviruses are a family of viruses that cause disease in mammals and birds. In humans, coronaviruses cause infections on the respiratory tract that can be fatal. These viruses can cause both mild illnesses such as the common cold and lethal illnesses ... ...

    Abstract Coronaviruses are a family of viruses that cause disease in mammals and birds. In humans, coronaviruses cause infections on the respiratory tract that can be fatal. These viruses can cause both mild illnesses such as the common cold and lethal illnesses such as SARS, MERS, and COVID-19. Air transmission represents the principal mode by which people become infected by SARS-CoV-2. To reduce the risks of air transmission of this powerful pathogen, we devised a method of inactivation based on the propagation of electromagnetic waves in the area to be sanitized. We optimized the conditions in a controlled laboratory environment mimicking a natural airborne virus transmission and consistently achieved a 90% (tenfold) reduction of infectivity after a short treatment using a Radio Frequency (RF) wave emission with a power level that is safe for people according to most regulatory agencies, including those in Europe, USA, and Japan. To the best of our knowledge, this is the first time that SARS-CoV-2 has been shown to be inactivated through RF wave emission under conditions compatible with the presence of human beings and animals. Additional in-depth studies are warranted to extend the results to other viruses and to explore the potential implementation of this technology in different environmental conditions.
    Mesh-Begriff(e) Animals ; Humans ; SARS-CoV-2 ; COVID-19 ; Microwaves ; Respiratory Aerosols and Droplets ; Europe ; Mammals
    Sprache Englisch
    Erscheinungsdatum 2023-06-27
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15071443
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  9. Artikel: In Vitro Antiviral Activity of Hyperbranched Poly-L-Lysine Modified by L-Arginine against Different SARS-CoV-2 Variants.

    Fiori, Federico / Cossu, Franca Lucia / Salis, Federica / Carboni, Davide / Stagi, Luigi / De Forni, Davide / Poddesu, Barbara / Malfatti, Luca / Khalel, Abbas / Salis, Andrea / Casula, Maria Francesca / Anedda, Roberto / Lori, Franco / Innocenzi, Plinio

    Nanomaterials (Basel, Switzerland)

    2023  Band 13, Heft 24

    Abstract: The emergence of SARS-CoV-2 variants requires close monitoring to prevent the reoccurrence of a new pandemic in the near future. The Omicron variant, in particular, is one of the fastest-spreading viruses, showing a high ability to infect people and ... ...

    Abstract The emergence of SARS-CoV-2 variants requires close monitoring to prevent the reoccurrence of a new pandemic in the near future. The Omicron variant, in particular, is one of the fastest-spreading viruses, showing a high ability to infect people and evade neutralization by antibodies elicited upon infection or vaccination. Therefore, the search for broad-spectrum antivirals that can inhibit the infectious capacity of SARS-CoV-2 is still the focus of intense research. In the present work, hyperbranched poly-L-lysine nanopolymers, which have shown an excellent ability to block the original strain of SARS-CoV-2 infection, were modified with L-arginine. A thermal reaction at 240 °C catalyzed by boric acid yielded Lys-Arg hyperbranched nanopolymers. The ability of these nanopolymers to inhibit viral replication were assessed for the original, Delta, and Omicron strains of SARS-CoV-2 together with their cytotoxicity. A reliable indication of the safety profile and effectiveness of the various polymeric compositions in inhibiting or suppressing viral infection was obtained by the evaluation of the therapeutic index in an in vitro prevention model. The hyperbranched L-arginine-modified nanopolymers exhibited a twelve-fold greater therapeutic index when tested with the original strain. The nanopolymers could also effectively limit the replication of the Omicron strain in a cell culture.
    Sprache Englisch
    Erscheinungsdatum 2023-12-06
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2662255-5
    ISSN 2079-4991
    ISSN 2079-4991
    DOI 10.3390/nano13243090
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  10. Artikel ; Online: Reply to Taylor et al. Comment on "Manna et al. SARS-CoV-2 Inactivation in Aerosol by Means of Radiated Microwaves.

    Manna, Antonio / De Forni, Davide / Bartocci, Marco / Pasculli, Nicola / Poddesu, Barbara / Lista, Florigio / De Santis, Riccardo / Amatore, Donatella / Grilli, Giorgia / Molinari, Filippo / Sangiovanni Vincentelli, Alberto / Lori, Franco

    Viruses

    2023  Band 15, Heft 10

    Abstract: SARS-CoV-2 is inactivated in aerosol (its primary mode of transmission) by means of radiated microwaves at frequencies that have been experimentally determined. Such frequencies are best predicted by the mathematical model suggested by Taylor, ... ...

    Abstract SARS-CoV-2 is inactivated in aerosol (its primary mode of transmission) by means of radiated microwaves at frequencies that have been experimentally determined. Such frequencies are best predicted by the mathematical model suggested by Taylor, Margueritat and Saviot. The alignment between such mathematical prediction and the outcomes of our experiments serves to reinforce the efficacy of the radiated microwave technology and its promise in mitigating the transmission of SARS-CoV-2 in its naturally airborne state.
    Mesh-Begriff(e) Humans ; SARS-CoV-2 ; COVID-19 ; Microwaves ; Respiratory Aerosols and Droplets ; Models, Theoretical
    Sprache Englisch
    Erscheinungsdatum 2023-10-18
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15102111
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang